Company / Current Liabilities
TG Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$153.8M
FY2025
5-year range
$53.2M / $153.8M
FY2021-FY2025
Trend
+69.6%
vs FY2024
Sector context
#70 of 213
Health Care
What the data says
At $154M, TG Therapeutics, Inc.'s current liabilities ranks #144 of 213 in the Health Care sector. Current Liabilities has increased for 3 consecutive years, from $53M in FY2022 to $154M in FY2025.
Based on SEC 10-K filings.
$154M in FY2025 with a 5-year CAGR of +11.9%.
Increased from $54M to $154M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +42.4%
- 5-Year CAGR
- +11.9%
- 10-Year CAGR
- -
Sector benchmark
#144 of 213 in Health CareTop 67% of 213This company $153.8M Sector average $1.6B
▼
-90.3% below sector average
Key checks
Key Insights
- TG Therapeutics, Inc.'s current liabilities has grown for 3 consecutive years.
- 5-year CAGR of +11.9%, indicating consistent growth.
- In FY2025, current liabilities increased 69.6% year-over-year.
- Ranks #70 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $153.8M | +69.6% |
| FY2024 | $90.7M | +68.8% |
| FY2023 | $53.7M | +1.0% |
| FY2022 | $53.2M | -18.6% |
| FY2021 | $65.4M | -25.3% |
| FY2020 | $87.6M | +3.7% |
| FY2019 | $84.4M | +117.3% |
| FY2018 | $38.9M | +39.0% |
| FY2017 | $28.0M | +65.6% |
| FY2016 | $16.9M | +60.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026